by Alex Kadhim
Reporting in Cancer Immunology Research, researchers have demonstrated that potent cytotoxic tumor-infiltrating lymphocytes (TILs) can be generated from immune-excluded chondrosarcomas using...
by Alex Kadhim
Researchers at Northwestern University, with collaborators from the University of Chicago and McGaw Medical Center, have reported the first known case of tumor-infiltrating lymphocyte (TIL)...
by Alex Kadhim
This real-world study demonstrates that lifileucel TIL therapy can deliver strong responses in advanced melanoma, with high response rates and encouraging survival among treated patients. However,...
by Alex Kadhim
New findings highlight proteostasis as a key driver of T cell differentiation and antitumor function, identifying protein-quality control as a critical factor in preventing T cell exhaustion. By...
by C. Brooke Adams, PharmD, BCOP
The cellular therapy landscape continues to evolve beyond hematologic malignancies, now making significant progress in solid tumor treatment.
Certain characteristics seen in solid tumors...
by Oncology On the Go and ASTCT Talks
A panel of oncology pharmacists discusses the role oflifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.